Last reviewed · How we verify
CLARITHROMYCIN
CLARITHROMYCIN is a Macrolide Antimicrobial [EPC] drug. It is currently FDA-approved (first approved 1991).
At a glance
| Generic name | CLARITHROMYCIN |
|---|---|
| Drug class | Macrolide Antimicrobial [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1991 |
Approved indications
Common side effects
- abdominal pain
- headache
- diarrhea
- dyspepsia
- flatulence
- nausea
- vomiting
- rash
- taste perversion
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis (PHASE1, PHASE2)
- Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
- Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication (NA)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CLARITHROMYCIN CI brief — competitive landscape report
- CLARITHROMYCIN updates RSS · CI watch RSS
Frequently asked questions about CLARITHROMYCIN
What is CLARITHROMYCIN?
CLARITHROMYCIN is a Macrolide Antimicrobial [EPC] drug.
What drug class is CLARITHROMYCIN in?
CLARITHROMYCIN belongs to the Macrolide Antimicrobial [EPC] class. See all Macrolide Antimicrobial [EPC] drugs at /class/macrolide-antimicrobial-epc.
When was CLARITHROMYCIN approved?
CLARITHROMYCIN was first approved on 1991.
What development phase is CLARITHROMYCIN in?
CLARITHROMYCIN is FDA-approved (marketed).
What are the side effects of CLARITHROMYCIN?
Common side effects of CLARITHROMYCIN include abdominal pain, headache, diarrhea, dyspepsia, flatulence, nausea.
Related
- Drug class: All Macrolide Antimicrobial [EPC] drugs
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing